-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with sickle cell disease (SCD) or cancer with bone metastases often go to the emergency department (ED) for severe pain, and opioid analgesics are still the first-line treatment for ED or acute pain after discharge
Patients with sickle cell disease (SCD) or cancer with bone metastases often go to the emergency department (ED) for severe pain, and opioid analgesics are still the first-line treatment for ED or acute pain after discharge
Some researchers investigated the association between the changes in the rate of opioid acquisition of these patients after the PDMP directive was implemented, and the results of the study were published in the latest JAMA journal
JAMA
The researchers used claims data from the Health Costs Institute (HCCI) from 2011 to 2017, which covered 27% of individual commercial insurance in the United States in 2017
The results of the study included the possibility of opioid ration after ED and the milligram equivalents of morphine (MMEs) of opioid ration
The study sample included 18345 EDs in 6239 SCD patients and 26427 EDs in 14389 patients with bone metastases
15.
According to the prescription drug monitoring program, the opioid equivalent of morphine milligrams issued after the emergency
According to the prescription drug monitoring program, the opioid equivalent of morphine milligrams issued after the emergencyComprehensive PDMP instructions are associated with a significant reduction in opioid use in SCD patients or cancer patients with bone metastases after ED
Comprehensive PDMP instructions are associated with a significant reduction in opioid use in SCD patients or cancer patients with bone metastases after ED
References: Zhang H, Kilaru AS, Meisel ZF, Bao Y.
Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis.
JAMA.
Published online June 14, 2021.
doi: 10.
1001/jama.
2021.
10161 Zhang H, Kilaru AS, Meisel ZF, Bao Y.
Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis.
JAMA.
Published online June 14, 2021.
doi:10.
1001/jama.
2021.
10161 doi:10.
1001/jama.
2021.
10161
leave a message here
